메뉴 건너뛰기




Volumn 18, Issue 5, 2012, Pages 1000-1005

Mechanistic understanding in clinical practice: Complementing evidence-based medicine with personalized medicine

Author keywords

clinical decision making; evidence based medicine; P medicine

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EVEROLIMUS; PANITUMUMAB; PAZOPANIB; SORAFENIB; SUNITINIB;

EID: 84866647476     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2012.01907.x     Document Type: Article
Times cited : (13)

References (29)
  • 1
    • 0142120646 scopus 로고    scopus 로고
    • Are all evidence-based practices alike? Problems in the ranking of evidence
    • Upshur, R. E. G., (2003) Are all evidence-based practices alike? Problems in the ranking of evidence. Canadian Medical Association Journal, 169 (7), 672-673.
    • (2003) Canadian Medical Association Journal , vol.169 , Issue.7 , pp. 672-673
    • Upshur, R.E.G.1
  • 5
    • 0032200198 scopus 로고    scopus 로고
    • Evidence-based medicine: A Kuhnian perspective of a transvestite non-theory
    • Couto, J. S., (1998) Evidence-based medicine: a Kuhnian perspective of a transvestite non-theory. Journal of Evaluation in Clinical Practice, 4 (4), 267-275.
    • (1998) Journal of Evaluation in Clinical Practice , vol.4 , Issue.4 , pp. 267-275
    • Couto, J.S.1
  • 7
    • 84866693521 scopus 로고    scopus 로고
    • Cartwright, N. Goldfinch, A. & Howick, J. (eds)Milan: Graduate Conference of the Graduate School in Social Sciences.
    • Cartwright, N., Goldfinch, A., &, Howick, J., (eds) (2007) Evidence-Based Policy: Where is Our Theory of Evidence? Milan: Graduate Conference of the Graduate School in Social Sciences.
    • (2007) Evidence-Based Policy: Where Is Our Theory of Evidence?
  • 9
    • 0141558233 scopus 로고    scopus 로고
    • What evidence in evidence-based medicine?
    • Worrall, J., (2002) What evidence in evidence-based medicine? Philosophy of Science, 69 (Suppl.), S316-S330.
    • (2002) Philosophy of Science , vol.69 , Issue.SUPPL.
    • Worrall, J.1
  • 10
    • 0028923154 scopus 로고
    • Grey zones of clinical practice: Some limits to evidence-based medicine
    • Naylor, C. D., (1995) Grey zones of clinical practice: some limits to evidence-based medicine. Lancet, 345, 840-842.
    • (1995) Lancet , vol.345 , pp. 840-842
    • Naylor, C.D.1
  • 11
    • 79951481957 scopus 로고    scopus 로고
    • Initial impact of the sequencing of the human genome
    • Lander, E. S., (2011) Initial impact of the sequencing of the human genome. Nature, 470, 187-197.
    • (2011) Nature , vol.470 , pp. 187-197
    • Lander, E.S.1
  • 14
    • 84859839784 scopus 로고    scopus 로고
    • Personalized management of patients with solid cancers: Moving from patient characteristics to tumor biology
    • Awada, A., Vandone, A. M., &, Aftimos, P., (2012) Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Molecular Biology, 24, 297-304.
    • (2012) Molecular Biology , vol.24 , pp. 297-304
    • Awada, A.1    Vandone, A.M.2    Aftimos, P.3
  • 15
    • 84859377987 scopus 로고    scopus 로고
    • Role of randomized phase III trials in an era of effective targeted therapies
    • Sharma, M. R., &, Schilsky, R. L., (2012) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews. Clinical Oncology, 9 (4), 208-214.
    • (2012) Nature Reviews. Clinical Oncology , vol.9 , Issue.4 , pp. 208-214
    • Sharma, M.R.1    Schilsky, R.L.2
  • 16
    • 0029912547 scopus 로고    scopus 로고
    • Why we need observational studies to evaluate the effectiveness of health care
    • Black, N., (1996) Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal, 312, 1215-1218.
    • (1996) British Medical Journal , vol.312 , pp. 1215-1218
    • Black, N.1
  • 18
    • 0027117969 scopus 로고
    • Department of Health and Human Services. New drug, antibiotic, and biological drug product regulations; Accelerated approval-FDA. Final rule
    • Food and Drugs Administration (FDA).
    • Food and Drugs Administration (FDA) (1992) Department of Health and Human Services. New drug, antibiotic, and biological drug product regulations; accelerated approval-FDA. Final rule. Federal Register, 57, 58942-58960.
    • (1992) Federal Register , vol.57 , pp. 58942-58960
  • 19
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)
    • Eisenhauer, E. A., Therasse, P., Bogaerts, J., et al,. (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). European Journal of Cancer, 45 (2), 228-247.
    • (2009) European Journal of Cancer , vol.45 , Issue.2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 20
    • 84858396530 scopus 로고    scopus 로고
    • Redefining clinical trials: The age of personalized medicine
    • Vaidyanathan, G., (2012) Redefining clinical trials: the age of personalized medicine. Cell, 148, 2011-2012.
    • (2012) Cell , vol.148 , pp. 2011-2012
    • Vaidyanathan, G.1
  • 21
    • 84860443404 scopus 로고    scopus 로고
    • Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design
    • Verweij, J., de Jonge, M., Eskens, F., &, Sleijfer, S., (2012) Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. Molecular Oncology, 6 (2), 196-203.
    • (2012) Molecular Oncology , vol.6 , Issue.2 , pp. 196-203
    • Verweij, J.1    De Jonge, M.2    Eskens, F.3    Sleijfer, S.4
  • 22
    • 84859438079 scopus 로고    scopus 로고
    • Hurdles in anticancer drug development from a regulatory perspective
    • Jonsson, B., &, Bergh, J., (2012) Hurdles in anticancer drug development from a regulatory perspective. Nature Reviews. Clinical Oncology, 9 (4), 236-243.
    • (2012) Nature Reviews. Clinical Oncology , vol.9 , Issue.4 , pp. 236-243
    • Jonsson, B.1    Bergh, J.2
  • 24
    • 84859441677 scopus 로고    scopus 로고
    • Drug development and clinical trials - The path to an approved cancer drug
    • Rubin, E. H., &, Gilliland, D. G., (2012) Drug development and clinical trials-the path to an approved cancer drug. Nature Reviews. Clinical Oncology, 9 (4), 215-222.
    • (2012) Nature Reviews. Clinical Oncology , vol.9 , Issue.4 , pp. 215-222
    • Rubin, E.H.1    Gilliland, D.G.2
  • 25
    • 79952267810 scopus 로고    scopus 로고
    • Traditional drug-discovery model ripe for reform
    • Cressey, D., (2011) Traditional drug-discovery model ripe for reform. Nature, 471, 17-18.
    • (2011) Nature , vol.471 , pp. 17-18
    • Cressey, D.1
  • 26
    • 84866713197 scopus 로고    scopus 로고
    • Studies in history and philosophy of biological and biomedical sciences
    • Craver, C. F. & Darden, L. (eds).
    • Craver, C. F., &, Darden, L., (eds) (2005) Studies in history and philosophy of biological and biomedical sciences. Special Issue: Mechanisms in Biology, 31 (2).
    • (2005) Special Issue: Mechanisms in Biology , vol.31 , pp. 2
  • 27
    • 0024502741 scopus 로고
    • Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of the data from 157 cases
    • Bayes de Luna, A., Coumel, P., &, Leclercq, J. F., (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of the data from 157 cases. American Hearth Journal, 117, 151-159.
    • (1989) American Hearth Journal , vol.117 , pp. 151-159
    • Bayes De Luna, A.1    Coumel, P.2    Leclercq, J.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.